Dr. Schwab is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Genentech
1 Dna Way
South San Francisco, CA 94080
Summary
- I am a medical oncologist with 16 years experience treating patients with breast cancer and conducting academic clinical research. I have taken my expertise to Genentech where I continue to focus on improving outcomes for patients with breast cancer, now entirely focused on developing new, better medications to treat this disease.
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2000 - 2003
Albert Einstein College of MedicineClass of 2000
University of California, BerkeleyBA, Molecular Cell Biology, 1991 - 1995
Certifications & Licensure
CA State Medical License 2001 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Early Clinical Trials Award “A Biomarker Study of Mifepristone in Early Stage Breast Cancer.” UCSD Moores Cancer Center, 2010-2011
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Publications & Presentations
PubMed
- 1 citationsCorrection: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-03-13 - 2 citationsA phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-02-26 - 5 citationsAssociation of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.Barbara A Parker, Rebecca A Shatsky, Richard B Schwab, Anne M Wallace,
Breast Cancer Research and Treatment. 2023-06-01
Press Mentions
Talking Breast Cancer for Men’s Health Awareness WeekJune 14th, 2017
Molecular Tumor Board Helps in Advanced Cancer CasesMay 5th, 2014
Committees
- Clinic Medical Director, UC San Diego Moores Cancer Center 2016 - Present
- UCSD Chair, Internal Advisory Committee, SDSU/UCSD Cancer Center Comprehensive Partnership 2016 - Present
- Occult Primary, NCCN Guidelines Committee Member 2014 - Present
- OPT-822 (Globo H-KLH) Phase II/III Study, Steering Committee Member 2012 - Present
External Links
- UC San Diego Healthhttp://providers.ucsd.edu/details/11447/richard-schwab-cancer-hematology_blood_diseases-la_jolla
- UC San Diegohttp://profiles.ucsd.edu/richard.schwab
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
